News | May 30, 2014

CardiAQ Reports Successful First-in-Human Transapical Implantation of its Second-Generation Valve

May 30, 2014 — CardiAQ Valve Technologies announced it successfully implanted its second-generation transcatheter mitral valve (TMVI) using the company’s newly added transapical delivery system. CardiAQ previously performed the first ever transfemoral transcatheter mitral valve implantation procedure in June 2012 with its self-conforming, self-anchoring implant technology. The transapical TMVI procedure was performed on an 88-year-old female suffering from severe mitral regurgitation (MR 4+) at The Heart Centre, Rigshospitalet University Hospital, Copenhagen, Denmark, by interventional cardiologists Lars Søndergaard, M.D., echocardiographer Nikolaj Ihlemann, M.D., cardiothoracic surgeons Peter Skov Olsen, M.D., Susanne Holme, M.D., and Arshad Quadri, M.D., and anesthesiologist Peter Bo Hansen, M.D.

“We are grateful to have had the opportunity to work with the CardiAQ technology again in order to provide treatment to this patient for whom no other alternatives were available,” said Søndergaard. “Based on a number of risk and anatomical factors, neither traditional mitral valve surgery nor transcatheter repair with MitraClip were options for this patient. Through careful review and consideration, we determined that TMVI, using CardiAQ’s second-generation transcatheter mitral valve and its new transapical delivery system, could offer this patient a chance at a longer and more comfortable life. The valve was implanted successfully with excellent function. The patient is recovering uneventfully and already feels a marked reduction in symptoms.”

“CardiAQ’s second-generation transcatheter mitral valve builds upon the company’s proprietary method for anchoring the implant through leaflet engagement, chordal preservation and annular attachment, while offering greater durability, improved flow properties and a novel feature for the prevention of paravalvular leaks,” said Arshad Quadri, M.D., founder and CMO of CardiAQ Valve Technologies.

“In the past few years, the potential of TMVI has become increasingly clear. As the first company to utilize the subvalvular apparatus in our attachment method, CardiAQ has set the standard for TMV anchoring,” said Brent Ratz, co-founder, president and COO of CardiAQ. “With the benefit of our first-generation first-in-human experience in 2012, we have gone on to further optimize our implant, incorporating all that we have learned into our second-generation TMV technology.”

For more information:

Related Content

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Sponsored Content | Videos | Heart Valve Technology| August 30, 2017
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest
PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init